Cardiac Amyloid Biorepository
study id #: NCT05521503
condition: Cardiac Amyloidosis
status: Recruiting
purpose:Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by cardiac amyloidosis and therapeutic interventions.
results: https://clinicaltrials.gov/ct2/show/results/NCT05521503
last updated: February 22, 2024
start date: December 21, 2021
estimated completion: December 2027
last updated: August 22, 2023
size / enrollment: 400
study description: This is a prospective study enrolling patients referred for or undergoing cardiac amyloidosis or cardiovascular treatment at the University of Kentucky. The study aims to facilitate the discovery of novel diagnostic biomarkers and therapeutic targets and improve the pathophysiological understanding of cardiac amyloidosis.
primary outcomes:
- Discover and quantify the concentration of novel diagnostic and prognostic biomarkers
Use biospecimens procured from patients with cardiac amyloidosis to identify diagnostic surrogate biomarkers using discovery proteomics. The serum levels will be compared between confirmed ATTR and non-ATTR heart failure patients and a diagnostic threshold will be established. - 12/21/2021-12/31/2027
inclusion criteria:
• Eligible Sexes: all
All patients undergoing treatment for cardiac amyloidosis or receiving a right heart catheterization who are at least 18 years of age.
exclusion criteria: Criteria:
Patients without a cardiovascular or amyloidosis diagnosis, under 18 years of age.
sponsor: Andrew Kolodziej
contacts: Andrew R Kolodziej, MD, (859) 562-0902, [email protected]
investigators: Andrew R Kolodziej, MD,University Of Kentucky
trial center locations: United States
-
United States, Kentucky
University of Kentucky
Andrew Kolodziej, MD, 859-562-0902, [email protected]
-
Financial Assistance by Paula Schmitthttps://www.youtube.com/watch?v=DUgtTLGZ...
-
Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and TherapyImmunoglobulin amyloid light-chain (AL) ...
-
International Myeloma FoundationThe International Myeloma Foundation (IM...
-
Patient Access Network (PAN) FoundationThe PAN Foundation is an independent, ...
-
Neuroarthropathy of the Foot Revealing Primary Systemic Amyloidosis: Case Report and Literature ReviewThe aims of this review were to describe...
-
Yvonne Efebera, MDYvonne Efebera serves as the Director of...
-
Q&A Session 2 – ASG Webinar 13/13https://www.youtube.com/watch?v=NrEjyVeJ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.